Intravitreal bevacizumab (avastin) for persistent new vessels in diabetic retinopathy (IBEPE study): 1-year results

Retina

Volumn 33, Issue 6, 2013, Pages 1109-1116

  Cintra, Léssia P ^a   Costa, Rogério A ^a,b   Ribeiro, Jefferson A S ^a   Calucci, Daniela ^a,b   Scott, Ingrid U ^c   Messias, André ^a   Jorge, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brazilian Center of Visual Sciences   (Brazil)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

angiogenesis; bevacizumab; diabetes; photocoagulation; retinopathy; VEGF

Indexed keywords

BEVACIZUMAB; FLUORESCEIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; PANRETINAL PHOTOCOAGULATION; PROSPECTIVE STUDY; RETINA NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84878914414     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31827b63f3     Document Type: Article

References (35)

1. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98:823-833.
2. Vander JF, Duker JS, Benson WE, et al. Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991;98:1575-1579.
3. Flynn HW Jr, Chew EY, Simons BD, et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. Ophthalmology 1992;99:1351-1357.
4. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-785.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
6. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118: 445-450. (Pubitemid 24307211)
7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487. (Pubitemid 24356306)
8. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-1482. (Pubitemid 24350514)
9. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385. (Pubitemid 34171588)
10. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996;114:964-970. (Pubitemid 26271462)
11. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828. (Pubitemid 26403735)
12. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71. (Pubitemid 26026196)
13. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457-10461.
14. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-28. (Pubitemid 43021723)
15. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354. (Pubitemid 44318195)
16. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155-158.
17. Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for highrisk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385-389.
18. Mason JO III, Yunker JJ, Vail R, et al. Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulationinduced complications in patients with severe proliferative diabetic retinopathy. Retina 2008;28:1319-1324.
19. Cho WB, Oh SB, Moon JW, et al. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009;29:516-522.
20. Schmidinger G, Maar N, Bolz M, et al. Repeated intravitreal bevacizumab (Avastin) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol 2011;89:76-81.
21. Ramos-Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol 2011;89:e567-e572.
22. Jorge R, Oliveira RS, Messias A, et al. Ranibizumab for retinal neovascularization. Ophthalmology 2011;118:1004-1005.
23. Ma Y, Zhang Y, Zhao T, et al. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol 2012;153:307-313.e2.
24. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988;95:1307-1320.
25. Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS report number 3. Int Ophthalmol Clin 1987;27:254-264.
26. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA 2003;290:197]. JAMA 2003;289:2560-2572. (Pubitemid 37430158)
27. Chylack LT, Wolfe JK, Singer DM, et al. The lens opacities classification system III. Arch Ophthalmol 1993;111:831-836. (Pubitemid 23170599)
28. Ribeiro JAS, Messias AMV, Scott IU, et al. Alternative technique for reducing compound waste during intravitreal injections. Arq Bras Oftalmol 2009;72:641-644.
29. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-1013. (Pubitemid 44973219)
30. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114: 2179-2182. (Pubitemid 350181137)
31. Emmanuele N, Sacks J, Klein R, et al. Veterans affairs diabetes trial group. Diabetes Care 2005;28:1954-1958.
32. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
33. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12- month data: report 2. Ophthalmology 2010;117:1078-1086.
34. Chun DW, Heier JS, Topping TM, et al. Pilot study of multiple intravitreal injections of ranibizumab in patients with centerinvolving clinically significant diabetic macular edema. Ophthalmology 2006;113:1707-1712.
35. Mason JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688. (Pubitemid 44442055)